Patent US4898737A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4898737A Expired / Lapsed US ⏱️ 0.0 years remaining

Controlled absorption pharmaceutical composition

Assignee: Perrigo Co PLC
•
Filing: 1988-04-27
•
Granted: 1990-02-06
•
Expires: 2008-04-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A sustained absorption propranolol-containing pellet for oral administration comprises a core of propranolol or a pharmaceutically acceptable salt thereof and an organic acid embedded in a polymeric material in a multi-layer arrangement and an outer membrane which permits release of the propranolol at a controlled rate in an aqueous medium. The pellet has a dissolution rate in vitro in an aqueous medium, which when measured in a basket assembly according to U.S. Pharmacopoeia XX at 37° C. and 75 r.p.m., is not more than 15% of the total propranol after 2 hours of measurement in a buffer solution at pH 7.5. Not more than 30% of the total propranolol is released after a total of 4 hours of measurement and not more than 63% of the total propranolol is released after a total of 6 hours.

Inventors

  • 👤 Donald E. Panoz
  • 👤 Edward J. Geoghegan

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 17:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078; A61P; A61P9/00

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 338 words
A controlled absorption propranolol containing pellet for oral administration, said pellet comprising: (A) a core of (i) a powder mixture comprising propranolol or a pharmaceutically acceptable salt thereof and an organic acid selected from the group consisting of citric acid, tartaric acid, succinic acid, malic acid, ascorbic acid and fumaric acid or a mixture thereof, and (ii) a polymeric material comprising a major proportion of a pharmaceutically acceptable water-soluble polymer and a minor proportion of a pharmaceutically acceptable water-insoluble polymer, said core comprising layers of said powder mixture and said polymeric material superimposed one upon the other wherein said polymeric material is present in an amount sufficient to ensure that all of said powder mixture is coated into said core; and (B) a multi-layer membrane surrounding said core and containing a major proportion of a pharmaceutically acceptable film forming, water-insoluble polymer and a minor proportion of a pharmaceuticaly acceptable film forming, water-soluble polymer, the number of layers in said membrane and the ratio of said water-insoluble polymer to said water-soluble polymer being effective to permit release of said propranolol from said pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration, said rate being measured in vitro as a dissolution rate of said pellet in a buffer solution at pH 7.5 which, when measured in a basket assembly according to U.S. Pharmacopoeia XX at 37° C. and 75 r.p.m., substantially corresponds to the following dissolution pattern: (a) from 0 to 15% of the total propranolol is released after 2 hours of measurement in said assembly; (b) from 15 to 30% of the total propranolol is released after 4 hours of measurement in said assembly; (c) from 43 to 63% of the total propranolol is released after 6 hours of measurement in said assembly; (d) from 75 to 100% of the total propranolol is released after 8 hours of measurement in said assembly; (e) from 85 to 100% of the total propranolol is released after 10 hours of measurement in said assembly.
Claim 2
Dependent Claim 338 words
A controlled absorption propranolol containing pellet for oral administration, said pellet comprising: (A) a core of (i) a powder mixture comprising propranolol or a pharmaceutically acceptable salt thereof and an organic acid selected from the group consisting of citric acid, tartaric acid, succinic acid, malic acid, ascorbic acid and fumaric acid or a mixture thereof, and (ii) a polymeric material comprising a major proportion of a pharmaceutically acceptable water-soluble polymer and a minor proportion of a pharmaceutically acceptable water-insoluble polymer, said core comprising layers of said powder mixture and said polymeric material superimposed one upon the other wherein said polymeric material is present in an amount sufficient to ensure that all of said powder mixture is coated into said core; and (B) a multi-layer membrane surrounding said core and containing a major proportion of a pharmaceutically acceptable film forming, water-insoluble polymer and a minor proportion of a pharmaceuticaly acceptable film forming, water-soluble polymer, the number of layers in said membrane and the ratio of said water-insoluble polymer to said water-soluble polymer being effective to permit release of said propranolol from said pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration, said rate being measured in vitro as a dissolution rate of said pellet in a buffer solution at pH 7.5 which, when measured in a basket assembly according to U.S. Pharmacopoeia XX at 37° C. and 75 r.p.m., substantially corresponds to the following dissolution pattern: (a) from 0 to 15% of the total propranolol is released after 2 hours of measurement in said assembly; (b) from 15 to 30% of the total propranolol is released after 4 hours of measurement in said assembly; (c) from 43 to 63% of the total propranolol is released after 6 hours of measurement in said assembly; (d) from 75 to 100% of the total propranolol is released after 8 hours of measurement in said assembly; (e) from 85 to 100% of the total propranolol is released after 10 hours of measurement in said assembly.
Claim 3
Dependent Claim 16 words
A pellet according to claim 1, wherein the active ingredient of the core is propranolol hydrochloride.
Claim 4
Dependent Claim 19 words
A pellet according to claim 1, wherein the propranolol and organic acid are present in a ratio of 2:1.
Claim 5
Dependent Claim 28 words
A pellet according to claim 1, wherein the polymeric material of the core includes a major proportion of a pharmaceutically acceptable, water-soluble polymer selected from hydroxypropylmethycellulose and polyvinylpyrrolidone.
Claim 6
Dependent Claim 34 words
A pellet according to claim 4, wherein the polymeric material of the core includes a minor proportion, of a pharmaceutically acceptable, water-insoluble polymer selected from the group consisting of methylcellulose, ethylcellulose, propylcellulose and shellac.
Claim 7
Dependent Claim 26 words
A pellet according to claim 1, wherein the propranolol or pharmaceutically acceptable salt thereof, organic acid and polymeric material are built up on an inert core.
Claim 8
Dependent Claim 23 words
A pellet according to claim 6, wherein the inert core is a non-pareil seed having an average diameter in the range 0.3-0.7 mm.
Claim 9
Dependent Claim 29 words
A pellet according to claim 1, wherein the membrane includes a major proportion of pharmaceutically acceptable, water-insoluble polymer selected from the group consisting of methylcellulose, ethylcellulose, propylcellulose and shellac.
Claim 10
Dependent Claim 37 words
A pellet according to claim 8, wherein the membrane includes a minor proportion of a pharmaceutically acceptable, water-soluble polymer, the ratio of water-insoluble to water-soluble polymer being determined by the inherent solubility characteristics of the polymers selected.
Claim 11
Dependent Claim 19 words
A pellet according to claim 9, wherein the membrane consists of ethylcellulose and hydroxypropylmethylcellulose in a ratio of 9:1.
Claim 12
Dependent Claim 45 words
A pellet according to claim 9, wherein the membrane consists of a copolymer of acrylic and methacrylic acid esters which is slightly permeable to water and a copolymer of acrylic and methacrylic acid esters which is freely permeable to water in a ratio of 8:2.
Claim 13
Dependent Claim 19 words
A pellet according to claim 9, wherein the membrane consists of shellac and polyvinylpyrrolidone in a ratio of 9:1.
Claim 14
Dependent Claim 8 words
A capsule comprising pellets according to claim 1.
Claim 15
Dependent Claim 8 words
A tablet comprising pellets according to claim 1.
Claim 16
Dependent Claim 51 words
A pellet according to claim 1, wherein the polymeric material of the core comprises a major proportion of a copolymer of acrylic and methacrylic acid esters which is freely permeable to water and a minor proportion of a copolymer of acrylic and methacrylic acid esters which is slightly permeable to water.
Claim 17
Dependent Claim 45 words
A pellet according to claim 1, wherein the membrane consists of a copolymer of acrylic and methacrylic acid esters which is slightly permeable to water and a copolymer of acrylic and methacrylic acid esters which is freely permeable to water in a ratio of 8:2.

References Cited (Backward Citations)

US4150110A Cited
US4138475A Cited
GB2039737A Cited
US4248856A Cited
US4309406A Cited
US4248858A Cited
US4248857A Cited
US4309404A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-02-05 1993-08-07 1994-02-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-02-05 1997-08-07 1998-02-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-02-05 2001-08-07 2002-02-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag